Latest News and Press Releases

TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the...

TEL AVIV, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

TEL AVIV, Israel, April 25, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced that new data on VB-111 will be presented at the upcoming American Society of Clinical Oncology (ASCO)...

TEL AVIV, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the Independent Data Safety Monitoring Committee (DSMC) met to conduct its second safety...

TEL AVIV, Israel, April 04, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the presentation of new data on MOSPD2, a novel potential target in oncology. VBL's study,...

Phase 2 Study of VB-201 Shows Reduction in Liver Enzymes Data Presented Today at H.C. Wainwright Annual NASH Investor Conference TEL AVIV, Israel, April 03, 2017 (GLOBE NEWSWIRE) -- VBL...

TEL AVIV, Israel, March 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018Phase 3 Study of VB-111 in Ovarian Cancer Currently Expected to Begin Enrollment in the...

TEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that it will be hosting a Key Opinion Leader breakfast on new targets and immunotherapeutic...